icon-folder.gif   Conference Reports for NATAP  
  12th International HIV Drug Resistance Workshop
June 10-14, 2003, Los Cabos, Mexico
Back grey_arrow_rt.gif
12th International HIV Drug Resistance Workshop
  I arrived Tuesday afternoon, after a 7 hour flight, along with most of the approximate 100 resistance researchers and clinicians that are attending this conference. The conference is being held from June 10-14 in Los Cabos, Mexico. The reception was Tuesday nite and presentations, both oral and posters, start at 8am Wed June 11. The conference is at a hotel directly on the ocean. The area is quite remote and the views of the ocean from the hotel are quite dramatic. Telephone and internet connections are not easy here but I'll try to provide reporting. Of note, there are a number of interesting presentations on characterization of resistance for new drugs intended for patients with extensive protease inhibitor and NNRTI resistance: tipranavir, TMC-114 for PI resistance, TMC-125 for NNRTI resistance, T-1249 (second generation fusion inhibitor from Roche/Trimeris. These drugs are currently in clinical trials of phase II and III in patients with HIV. Except for the tipranavir studies which were conducted in a large number of patients because this drug is in phase III, the studies conducted are small, short-term and preliminary. The data presented here on resistance and antiviral activity for these drugs suggest preliminarily that these drugs will be potent and effective for many patients with extensive resistance to protease inhibitors and NNRTIs. The studies being presented here for these drugs show viral response for patients who are resistant to PIs or NNRTIs and the studies explain the resistance profiles of the patients showing they have extensive drug resistance. But these drugs were effective in these patients in reducing viral load despite extensive resistance. T-1249 was tested in patients with resistance to T-20 (Fuzeon).
Tipranavir is in phase III and is the closest to being available. TMC-114, TMC-125, and T-1249 are still in earlier stages of development (phase II).
There are presentations here on several drugs even in earlier stages of development that show early promise: elvucitabine (ACH-126,443 or Fd4C) is an L nucleoside analogue (AZT is a nucleoside analogue); a new Roche protease inhibitor (R0033-4649); new type of protease inhibitor (P-1946) still in pre-clinical testing.
Additional reporting and data from these studies will be forthcoming in reports from NATAP. Andrew Zolopa, MD from Stanford University and myself will be reporting from this conference.